Yimin Mao

1.5k total citations · 1 hit paper
52 papers, 729 citations indexed

About

Yimin Mao is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, Yimin Mao has authored 52 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 11 papers in Epidemiology. Recurrent topics in Yimin Mao's work include Pulmonary Hypertension Research and Treatments (12 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Yimin Mao is often cited by papers focused on Pulmonary Hypertension Research and Treatments (12 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Yimin Mao collaborates with scholars based in China, United States and Malaysia. Yimin Mao's co-authors include Xiaofang Li, Zhi‐Cheng Jing, Xin Jiang, Yingying Hao, Wenhui Wu, Yuanqiang Zhang, Aiping Cao, Lungen Lu, Kai Sun and Xue Zhang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Yimin Mao

45 papers receiving 716 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Yimin Mao

Since Specialization

Citations

This map shows the geographic impact of Yimin Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yimin Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yimin Mao more than expected).

Fields of papers citing papers by Yimin Mao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yimin Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yimin Mao. The network helps show where Yimin Mao may publish in the future.

Co-authorship network of co-authors of Yimin Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Yimin Mao. A scholar is included among the top collaborators of Yimin Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yimin Mao. Yimin Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pulmonary arterial hypertension: a long-standing and nonnegligible burden over three decades 2025 ·Science Bulletin ·Jiayong Qiu, (unknown), (unknown), (unknown), Chao Liu, (unknown), Yuejiao Ma, Yu‐Ping Zhou, (unknown), (unknown), Xiaowei Gong, Tongsheng Wang, Yimin Mao, Yang Yuan, (unknown), Zhi‐Cheng Jing	1
2	Development of a nomogram model to predict 30-day mortality in ICU cancer patients with acute pulmonary embolism 2025 ·Scientific Reports ·(unknown), (unknown), (unknown), Yimin Mao	0
3	Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1 2024 ·Journal of Translational Medicine ·Pengfei Gao, Yanjiao Lu, Kun Tang, Wei Wang, Tongsheng Wang, (unknown), (unknown), Yimin Mao	1
4	White blood cell-to-haemoglobin ratio as a predictor of 30-day mortality in ICU patients with pulmonary hypertension: a MIMIC-IV database study 2024 ·BMC Cardiovascular Disorders ·(unknown), (unknown), (unknown), Yimin Mao	0
5	Microbial signatures predictive of short-term prognosis in severe pneumonia 2024 ·Frontiers in Cellular and Infection Microbiology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Chong Xu, Yimin Mao, Yongmei Zhang	2
6	Association between coronary artery stenosis and myocardial injury in patients with acute pulmonary embolism: A case-control study 2024 ·Chinese Medical Journal ·(unknown), Chao Liu, (unknown), (unknown), (unknown), Dan Lü, Xinxin Yan, Xuan Gao, Jia Wang, (unknown), (unknown), (unknown), (unknown), (unknown), Yimin Mao, Xi‐Qi Xu, Tian‐Yu Lian, (unknown), Zhi‐Cheng Jing	0
7	Pathogenic Nocardia amamiensis infection: A rare case report and literature review 2023 ·Heliyon ·(unknown), (unknown), (unknown), (unknown), Yimin Mao	3
8	PU.1-CD23 signaling mediates pulmonary innate immunity against Aspergillus fumigatus infection by driving inflammatory response 2023 ·BMC Immunology ·Min Wang, Ming Zhang, (unknown), Chenyang Liu, (unknown), Tongsheng Wang, Yingmin Zhang, Yimin Mao	2
9	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial breakdown → 2022 ·Journal of Clinical Oncology ·Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaohong Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao	127
10	7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial 2022 ·Annals of Oncology ·C.Z. Zhou, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yimin Mao, Dan Wang, (unknown), Ailiang Zeng, (unknown), Y. Pan, Yunzhang Hu, Xinyi Zhang, (unknown), Yingying Du, (unknown), Zhongjun Liu	2
11	Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease 2022 ·Frontiers in Medicine ·Xiaofang Li, (unknown), Yimin Mao	9
12	Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension 2020 ·European Respiratory Journal ·Yangyang He, Yi Yan, Xin Jiang, Junhan Zhao, Zhe Wang, Tao Wu, Yong Wang, Shanshan Guo, Jue Ye, Tian‐Yu Lian, Xi‐Qi Xu, Jinlan Zhang, Kai Sun, Fu-Hua Peng, Yu‐Ping Zhou, Yimin Mao, Xue Zhang, Jiwang Chen, Yuanqiang Zhang, Zhi‐Cheng Jing	47
13	Efficacy and safety of Sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: A meta-analysis 2020 ·Life Sciences ·Yingying Hao, (unknown), Yimin Mao, (unknown), (unknown), (unknown), Min Wang, (unknown)	11
14	Emergence and Characterization of a Novel IncP-6 Plasmid Harboring blaKPC–2 and qnrS2 Genes in Aeromonas taiwanensis Isolates 2019 ·Frontiers in Microbiology ·Xinjun Hu, Xiao Yu, (unknown), Hao Xu, Lihua Guo, (unknown), (unknown), Li Song, Jifeng Sun, Yue Feng, Yimin Mao, Beiwen Zheng	23
15	GermlineBMP9mutation causes idiopathic pulmonary arterial hypertension 2018 ·European Respiratory Journal ·Xiaojian Wang, Tian‐Yu Lian, Xin Jiang, Shao‐Fei Liu, Suqi Li, Rong Jiang, Wenhui Wu, Jue Ye, (unknown), Yao Du, Xi-Qi Xu, Yan Wu, Fu-Hua Peng, Kai Sun, Yimin Mao, Huan Yu, Liang Chen, (unknown), Yuanqiang Zhang, Xue Zhang, Zhi‐Cheng Jing	90
16	Catheter-directed therapy as a treatment for submassive pulmonary embolism: A meta-analysis 2017 ·Life Sciences ·Xiaofang Li, (unknown), (unknown), (unknown), Danyang Li, (unknown), Yimin Mao	2
17	Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window 2016 ·Complementary Therapies in Medicine ·Jiansheng Li, Haifeng Wang, Suyun Li, Hailong Zhang, Xueqing Yu, Xiaoyun Zhang, Fengsen Li, Xianmei Zhou, (unknown), Yimin Mao, Li-Jun Ma, (unknown), (unknown), (unknown)	15
18	Brief communication (Original). Pulmonary embolism in patients with chronic obstructive pulmonary disease and exacerbations of unknown origin 2013 ·Asian Biomedicine ·Tongsheng Wang, (unknown), Yimin Mao, (unknown)	2
19	Expression of Mucin MUC5AC in Rats with Asthma and Mechanisms of Anti-inflammatory Effects of Erythromycin 2007 ·Yimin Mao	1
20	[The inhibitory effect of oxymatrine on hepatitis C virus in vitro]. 2001 ·PubMed ·(unknown), (unknown), Min Zeng, Ling Lu, Di Qu, Yimin Mao, (unknown), Hua Jiang	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact